Enalees, a company specialising in the design, development and marketing of state-of-the-art rapid molecular diagnostic tests for the veterinary industry, has been awarded a €500,000 ($489k) subsidy by the Île-de-France region as part of the France 2030 Investments for the Future Program.
This funding will help finance a €1.1 million ($1.08M) project to strengthen the production supply chain of its infectious diseases diagnostic kits for domesticated animals (horses, dogs and cats).
In 2021, Enalees increased its production capacity by purchasing four automated freeze-dryers, so that it can perform this production phase in France. The company can now oversee quality control at all stages, from design through to manufacturing. This subsidy will help strengthen Enalees’ position in its existing market by supporting the development - potentially in partnership with other local players - of more ergonomic microtubes, better suited for use in the field.
Enalees plans to expand its current 600m2 premises at the Genopole research centre (France) with a new 100m2 laboratory for this new production line. The production team will be in place by the start of 2023.
“This funding is vital for business growth as it allows us to increase our manufacturing capacities and to prepare for international expansion into European markets and beyond,” said Laurent Thiery, president and co-founder of Enalees.
Enalees’ molecular tests are used by veterinary professionals to help them diagnose infectious diseases quickly and accurately – both in their veterinary practices and in the field - without the need to send samples to an external laboratory. The tests are designed to detect DNA specific to the target pathogen thanks to an isothermal amplification method (Loop-mediated isothermal AMPlification Polymerase Chain Reaction - LAMP PCR). It produces a result after just 30 minutes of analysis. This enables animals to be treated more quickly and, if necessary, placed in isolation.
Thanks to this new funding, Enalees can now target new veterinary markets in Europe and beyond, where there is demand for more sensitive diagnostic tests. The company also plans to expand its range of diagnostic products for infectious diseases in domesticated animals.
Learn more about the company at www.enalees.com.
